Elekta outlines long-term strategy, shares anchored in cancer care technology

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 09:06.

Elekta (SE0000163628) remains a key name in listed cancer care technology. The Stockholm-based group competes with international peers such as Varian and Accuray in radiotherapy solutions for hospitals and clinics worldwide.

Radiotherapy specialist with global reach

Elekta focuses on precision radiotherapy and related oncology software, supplying linear accelerators and planning tools to cancer centers. The company reports that its systems are installed in more than 120 countries, reflecting a broad geographic footprint in advanced cancer treatment.

The Swedish medtech stock is part of a global peer group that includes Varian, now owned by Siemens Healthineers, and Accuray, both active on major trading venues such as NASDAQ for the US-listed names. This positioning underscores Elekta's role in the worldwide competition for radiotherapy equipment and software budgets.

Long-term cancer care demand

Demographic trends with aging populations and rising cancer incidence support sustained demand for radiotherapy capacity over the coming decades, according to analyses of global oncology care published by industry observers. Hospitals continue to invest in replacement and upgrade cycles for linear accelerators and planning systems as treatment protocols become more precise.

Global medtech benchmarks show that radiotherapy is a capital-intensive niche, with vendors such as Elekta typically generating revenue from equipment sales, software licenses, and long-term service contracts. For investors in healthcare stocks, these recurring elements are a central part of the equity story.

The product behind the stock

Elekta's core business revolves around radiotherapy systems such as linear accelerators and stereotactic radiosurgery solutions, combined with oncology information systems for treatment planning and workflow. These offerings generate revenue through hardware, software and long-term service agreements with cancer centers.

Where the stock trades today

The Elekta shares (SE0000163628) are listed on Nasdaq Stockholm, with the stock trading there in Swedish kronor. As of the latest available price snapshot on 2026-06-26, 16:30, the shares changed hands at 79.50 SEK on Nasdaq Stockholm.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.